Related Experiment Video
Updated: Jun 1, 2026
06:29
Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells
Published on: January 29, 2014
Complement (C1q) fixing solid-phase screening for HLA antibodies increases the availability of compatible platelet
Magali J Fontaine1, Jenny Kuo, Ge Chen
1Department of Pathology, Stanford Hospital and Clinics, Stanford University, Stanford, California 94305-5626, USA. magalif@stanford.edu
Transfusion
|May 28, 2011
Summary
A new complement component C1q assay improves platelet transfusion compatibility for highly sensitized patients. This method identifies clinically relevant HLA antibodies, increasing the availability of compatible platelet units and improving patient outcomes.
Area of Science:
- Immunology
- Transfusion Medicine
- Clinical Chemistry
Background:
- Immune refractoriness to platelet (PLT) transfusion is often caused by human leukocyte antigen (HLA) antibodies.
- Current immunoglobulin (Ig)G-single-antigen-bead (SAB) assays can be overly sensitive, making it difficult to find compatible donors for highly sensitized patients.
- A novel assay detecting HLA antibodies that bind complement component C1q was developed to address this limitation.
Purpose of the Study:
- To evaluate the clinical relevance of a C1q-SAB assay compared to the standard IgG-SAB assay in highly sensitized patients refractory to PLT transfusion.
- To determine if the C1q-SAB assay can better identify compatible PLT units and improve transfusion outcomes.
Main Methods:
- A retrospective analysis was conducted on 13 highly sensitized patients who received PLT units incompatible by the IgG-SAB method.
- Patient samples were retested using the C1q-SAB method to compare HLA antibody specificities and calculated percent reactive antibody (CPRA) values.
- Corrected count increment (CCI) was analyzed for C1q-compatible versus C1q-incompatible PLTs, with an evaluation of ABO compatibility impact.
Main Results:
- The mean CPRA was significantly lower using C1q-SAB (60%) compared to IgG-SAB (94%).
- Patients demonstrated significantly higher CCI with C1q-compatible PLTs (10.6 × 10^9 /L) than with C1q-incompatible PLTs (2.5 × 10^9 /L/m^2).
- Approximately 75% of PLT units previously deemed incompatible were found to be compatible using the C1q-SAB method.
Conclusions:
- The C1q-SAB assay is a more relevant method than IgG-SAB for identifying clinically significant HLA antibodies in highly refractory PLT transfusion patients.
- This assay improves the selection of compatible PLT units, leading to better transfusion efficacy as measured by CCI.
- The C1q-SAB assay enhances the availability of compatible PLTs for patients with challenging antibody profiles.
